Xenon Pharmaceuticals Inc (XENE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.48 Million) by net assets ($581.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Xenon Pharmaceuticals Inc (XENE) market capitalisation for the company's overall valuation and market capitalisation.
Xenon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xenon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore how high is Xenon Pharmaceuticals Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CleanSpark Inc
NASDAQ:CLSK
|
-0.148x |
|
Avicopter PLC
SHG:600038
|
-0.092x |
|
EQB Inc.
TO:EQB
|
-0.163x |
|
Ningbo Jintian Copper Group Co Ltd
SHG:601609
|
-0.009x |
|
Daeduck Electronics Co Ltd
KO:353200
|
0.113x |
|
Air France-KLM SA
PA:AF
|
0.357x |
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
0.167x |
|
INVENTURUS KNOWLEDGE SO L
NSE:IKS
|
0.042x |
Annual Cash Flow Conversion Efficiency for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Xenon Pharmaceuticals Inc from 2012 to 2025. View XENE live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.76 Million | $-279.12 Million | -0.480x | -99.68% |
| 2024-12-31 | $754.90 Million | $-181.39 Million | -0.240x | -53.42% |
| 2023-12-31 | $927.92 Million | $-145.33 Million | -0.157x | -14.80% |
| 2022-12-31 | $721.50 Million | $-98.43 Million | -0.136x | -7.97% |
| 2021-12-31 | $550.03 Million | $-69.50 Million | -0.126x | +55.01% |
| 2020-12-31 | $171.35 Million | $-48.12 Million | -0.281x | -457.67% |
| 2019-12-31 | $91.98 Million | $-4.63 Million | -0.050x | +85.02% |
| 2018-12-31 | $103.30 Million | $-34.72 Million | -0.336x | +57.95% |
| 2017-12-31 | $35.93 Million | $-28.73 Million | -0.799x | -161.07% |
| 2016-12-31 | $63.90 Million | $-19.57 Million | -0.306x | -3.24% |
| 2015-12-31 | $61.03 Million | $-18.10 Million | -0.297x | -8215.27% |
| 2014-12-31 | $72.78 Million | $266.00K | 0.004x | +102.65% |
| 2013-12-31 | $24.12 Million | $-3.32 Million | -0.138x | -103.82% |
| 2012-12-31 | $12.62 Million | $45.57 Million | 3.610x | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more